Pharsight

Drug Patents Expiring in 2029

1. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(4 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(4 years from now)

US8674825 OTSUKA Pharma-informatics system
Apr, 2029

(4 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode
Jul, 2029

(5 years from now)

US10441194 OTSUKA Ingestible event marker systems
Jul, 2029

(5 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier
Aug, 2029

(5 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification
Sep, 2029

(5 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers
Dec, 2029

(5 years from now)

US9149577 OTSUKA Body-associated receiver and method
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that co...

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Acanya patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220049 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US9078870 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US8895070 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US10624918 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US8663699 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US8288434 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Aug, 2029

(5 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 23 October, 2008

Treatment: Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of ACANYA before it's drug patent expiration?
More Information on Dosage

ACANYA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Actoplus Met patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320714 TAKEDA PHARMS USA Tablet
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-116) May 17, 2015

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ACTOPLUS MET family patents

Family Patents

4. Acuvail patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7842714 ABBVIE Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 22, 2012

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents

5. Adlyxin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855388 SANOFI-AVENTIS US Dosing and drive mechanism for drug delivery device
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ADLYXIN family patents

Family Patents

6. Afrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9446133 MANNKIND Dry powder inhaler and system for drug delivery
Jun, 2029

(4 years from now)

US10342938 MANNKIND Dry powder drug delivery system
Jun, 2029

(4 years from now)

US9192675 MANNKIND Dry powder inhaler and system for drug delivery
Jun, 2029

(4 years from now)

US9662461 MANNKIND Dry powder drug delivery system and methods
Jun, 2029

(4 years from now)

US8912193 MANNKIND Dry powder inhaler and system for drug delivery
Jun, 2029

(4 years from now)

US9393372 MANNKIND Dry powder drug delivery system
Jul, 2029

(5 years from now)

US8119593 MANNKIND Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin
Aug, 2029

(5 years from now)

US10046031 MANNKIND Use of ultrarapid acting insulin
Aug, 2029

(5 years from now)

US9943571 MANNKIND Use of ultrarapid acting insulin
Aug, 2029

(5 years from now)

US8258095 MANNKIND Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content
Aug, 2029

(5 years from now)

US8623817 MANNKIND Method of treating diabetes type 2 by administering ultrarapid acting insulin
Sep, 2029

(5 years from now)

US9339615 MANNKIND Dry powder inhaler and system for drug delivery
Oct, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: Use of an inhaler to administer dry powder medicament; Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin; Method of delivering to a patient wi...

Dosage: POWDER;INHALATION

More Information on Dosage

AFREZZA family patents

Family Patents

7. Agamree patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833159 CATALYST PHARMS Non-hormonal steroid modulators of NF-kB for treatment of disease
May, 2029

(4 years from now)

US8334279 CATALYST PHARMS Non-hormonal steroid modulators of NF-κB for treatment of disease
May, 2029

(4 years from now)

US10857161 CATALYST PHARMS Non-hormonal steroid modulators of NF-kB for treatment of disease
May, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 26, 2028
Orphan Drug Exclusivity(ODE-450) Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 27 October, 2027

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION;ORAL

More Information on Dosage

AGAMREE family patents

Family Patents

8. Akeega patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436185 JANSSEN BIOTECH Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

AKEEGA family patents

Family Patents

9. Aliqopa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8466283 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(5 years from now)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-155) Sep 14, 2024
Orphan Drug Exclusivity(ODE) Sep 14, 2024
New Chemical Entity Exclusivity(NCE) Sep 14, 2022

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: 14 September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

Family Patents

10. Alunbrig patents expiration

ALUNBRIG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-142) Apr 28, 2024
Orphan Drug Exclusivity(ODE-300) May 22, 2027
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
Orphan Drug Exclusivity(ODE) Apr 28, 2024
New Indication(I-847) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

ALUNBRIG family patents

Family Patents

11. Amvuttra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 13, 2027
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

Family Patents

12. Angiomax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7598343

(Pediatric)

SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(4 years from now)

US7582727

(Pediatric)

SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(4 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage

ANGIOMAX family patents

Family Patents

13. Anoro Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

14. Arnuity Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-290) Mar 01, 2026
New Strength(NS) May 17, 2021
New Patient Population(NPP) May 17, 2021
New Product(NP) Aug 20, 2017

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

15. Atripla patents expiration

ATRIPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598185 GILEAD SCIENCES Unitary pharmaceutical dosage form
Apr, 2029

(4 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage

ATRIPLA family patents

Family Patents

16. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610 KALEO INC Medical injector with compliance tracking and monitoring
Apr, 2029

(4 years from now)

US8021344 KALEO INC Medicament delivery device configured to produce an audible output
Nov, 2029

(5 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

17. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(5 years from now)

US8497378 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027
New Indication(I-815) Oct 24, 2022

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

BAXDELA family patents

Family Patents

18. Belsomra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-253) Jan 29, 2023
New Chemical Entity Exclusivity(NCE) Aug 13, 2019

Drugs and Companies using SUVOREXANT ingredient

NCE-1 date: 13 August, 2018

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

BELSOMRA family patents

Family Patents

19. Belviq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168624 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage

BELVIQ family patents

Family Patents

20. Belviq Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168624 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

21. Besivance patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062 BAUSCH AND LOMB Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2014

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

NCE-1 date: 28 May, 2013

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

BESIVANCE family patents

Family Patents

22. Braftovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
New Indication(I-826) Apr 08, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

23. Brenzavvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7838499 THERACOSBIO Benzylbenzene derivatives and methods of use
Jan, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

BRENZAVVY family patents

Family Patents

24. Breo Ellipta patents expiration

BREO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116721 GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Feb, 2029

(4 years from now)

US11116721

(Pediatric)

GLAXO GRP LTD Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026
M(M-202) May 15, 2020
New Product(NP) May 10, 2016
New Chemical Entity Exclusivity(NCE) May 10, 2018
New Indication(I-708) Apr 30, 2018

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

25. Brisdelle patents expiration

BRISDELLE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8658663 SEBELA IRELAND LTD Method of treating thermoregulatory disfunction with paroxetine
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 28, 2016

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage

BRISDELLE family patents

Family Patents

26. Bromsite patents expiration

Can you believe BROMSITE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999 SUN PHARM Non-steroidal anti-inflammatory ophthalmic compositions
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 08, 2019

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 08 April, 2016

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of BROMSITE before it's drug patent expiration?
More Information on Dosage

BROMSITE family patents

Family Patents

27. Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

28. Bydureon Pen patents expiration

BYDUREON PEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8827963 ASTRAZENECA AB Administering device with holding mechanism
Feb, 2029

(4 years from now)

US8690837 ASTRAZENECA AB Mixing device for a two-chamber ampoule
May, 2029

(4 years from now)

US8827963

(Pediatric)

ASTRAZENECA AB Administering device with holding mechanism
Aug, 2029

(5 years from now)

US8690837

(Pediatric)

ASTRAZENECA AB Mixing device for a two-chamber ampoule
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

29. Cabtreo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624918 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US10220049 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US9561208 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(4 years from now)

US8288434 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2026

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2023

Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older

Dosage: GEL;TOPICAL

More Information on Dosage

CABTREO family patents

Family Patents

30. Caldolor patents expiration

CALDOLOR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-128) Nov 19, 2024
New Patient Population(NPP) May 11, 2026
New Product(NP) Jun 11, 2012
New Dosing Schedule(D-152) Nov 20, 2018

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Management of mild to moderate pain, management of moderate to severe pain a...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

Family Patents

31. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48825 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(4 years from now)

US9586960 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(4 years from now)

US8648077 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199995 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Mar, 2029

(4 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US9168258 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(4 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2024
New Indication(I-882) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

32. Carnexiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9750822 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 07, 2023
Orphan Drug Exclusivity(ODE-124) Oct 07, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CARNEXIV family patents

Family Patents

33. Colcrys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Feb, 2029

(4 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 29, 2016
New Indication(I-603) Jul 30, 2012

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 29 July, 2009

Treatment: Method of treating gout flares; Method of administering colchicine to familial mediterranean fever patients; Method of using colchicine for the prophylaxis of gout flares

Dosage: TABLET;ORAL

How can I launch a generic of COLCRYS before it's drug patent expiration?
More Information on Dosage

COLCRYS family patents

Family Patents

34. Consensi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662315 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
May, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 31, 2021

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

How can I launch a generic of CONSENSI before it's drug patent expiration?
More Information on Dosage

CONSENSI family patents

Family Patents

35. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8088786 NALPROPION Layered pharmaceutical formulations
Feb, 2029

(4 years from now)

US11324741 NALPROPION Methods for treating visceral fat conditions
May, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

36. Copiktra patents expiration

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods
Jan, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-208) Sep 24, 2025
Orphan Drug Exclusivity(ODE-209) Sep 24, 2025
New Chemical Entity Exclusivity(NCE) Sep 24, 2023

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 24 September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

Family Patents

37. Cotellic patents expiration

COTELLIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
Pediatric Exclusivity(PED) Jan 28, 2026
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

38. Daklinza patents expiration

DAKLINZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8329159 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Jul, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-727) Feb 05, 2019
New Indication(I-726) Feb 05, 2019
New Chemical Entity Exclusivity(NCE) Jul 24, 2020
New Dosing Schedule(D-161) Feb 05, 2019
New Dosing Schedule(D-162) Feb 05, 2019

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DAKLINZA family patents

Family Patents

39. Desyrel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8133893 PRAGMA Trazodone and trazodone hydrochloride in purified form
Mar, 2029

(4 years from now)

How can I launch a generic of DESYREL before it's drug patent expiration?
More Information on Dosage

DESYREL family patents

Family Patents

40. Dexilant Solutab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

41. Dojolvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027
New Chemical Entity Exclusivity(NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

DOJOLVI family patents

Family Patents

42. Dovato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

43. Duaklir Pressair patents expiration

DUAKLIR PRESSAIR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000517 COVIS Dosage and formulation
Mar, 2029

(4 years from now)

US10085974 COVIS Dosage and formulation
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

44. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799336 ABBVIE Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

45. Dutrebis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(5 years from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage

DUTREBIS family patents

Family Patents

46. Duzallo patents expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Apr, 2029

(4 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Aug, 2029

(5 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Dec, 2029

(5 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

47. Dyanavel Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 19, 2018

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR family patents

Family Patents

48. Ella patents expiration

ELLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735380 LAB HRA PHARMA Ulipristal acetate tablets
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-271) Jun 24, 2024
New Chemical Entity Exclusivity(NCE) Aug 13, 2015

Drugs and Companies using ULIPRISTAL ACETATE ingredient

NCE-1 date: 13 August, 2014

Market Authorisation Date: 13 August, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage

ELLA family patents

Family Patents

49. Embeda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623418 ALPHARMA PHARMS Pharmaceutical composition
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Treatment of moderate to severe chronic pain by administering an intact composition as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage

EMBEDA family patents

Family Patents

50. Entereg patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8645160 CUBIST PHARMS Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug
Jun, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-128) Oct 18, 2016
New Chemical Entity Exclusivity(NCE) May 20, 2013

Drugs and Companies using ALVIMOPAN ingredient

NCE-1 date: 20 May, 2012

Market Authorisation Date: 20 May, 2008

Treatment: Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection ...

Dosage: CAPSULE;ORAL

How can I launch a generic of ENTEREG before it's drug patent expiration?
More Information on Dosage

ENTEREG family patents

Family Patents

51. Eohilia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050368 TAKEDA PHARMS USA Corticosteroid compositions
Aug, 2029

(5 years from now)

US8324192 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-466) Feb 09, 2031
New Product(NP) Feb 09, 2027

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 09 February, 2024

Treatment: Treatment of eosinophilic esophagitis

Dosage: SUSPENSION;ORAL

More Information on Dosage

EOHILIA family patents

Family Patents

52. Epclusa patents expiration

EPCLUSA's oppositions filed in EPO
EPCLUSA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(4 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(4 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(5 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(5 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
M(M-264) Jul 14, 2023
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
M(M-277) Apr 27, 2025
Pediatric Exclusivity(PED) Dec 10, 2028
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Strength(NS) Mar 19, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 19 March, 2020

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

53. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits...

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

54. Eucrisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039451 ANACOR PHARMS INC Boron-containing small molecules
Jun, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039451

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-191) Apr 03, 2026
New Chemical Entity Exclusivity(NCE) Dec 14, 2021
Pediatric Exclusivity(PED) Sep 23, 2023
New Patient Population(NPP) Mar 23, 2023

Drugs and Companies using CRISABOROLE ingredient

NCE-1 date: 23 September, 2022

Market Authorisation Date: 14 December, 2016

Treatment: NA

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage

EUCRISA family patents

Family Patents

55. Evomela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 ACROTECH BIOPHARMA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9200088 ACROTECH BIOPHARMA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 10, 2023
Orphan Drug Exclusivity(ODE-110) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage

EVOMELA family patents

Family Patents

56. Evotaz patents expiration

EVOTAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374 BRISTOL Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of EVOTAZ before it's drug patent expiration?
More Information on Dosage

EVOTAZ family patents

Family Patents

57. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610 KALEO INC Medical injector with compliance tracking and monitoring
Apr, 2029

(4 years from now)

US8223610 KALEO INC Apparatus and method for initializing information recording medium, apparatus and method for recording information, and information recording medium
Apr, 2029

(4 years from now)

US8021344 KALEO INC Medicament delivery device configured to produce an audible output
Nov, 2029

(5 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

58. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610 KALEO INC Medical injector with compliance tracking and monitoring
Apr, 2029

(4 years from now)

US8021344 KALEO INC Medicament delivery device configured to produce an audible output
Nov, 2029

(5 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

59. Exondys 51 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47769 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Sep 19, 2023
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EXONDYS 51 family patents

Family Patents

60. Farxiga patents expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

61. Ferriprox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156 CHIESI Liquid formulation for deferiprone with palatable taste
Oct, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-859) Apr 30, 2024
Orphan Drug Exclusivity(ODE-417) Apr 30, 2028
Orphan Drug Exclusivity(ODE-419) Apr 30, 2028
Orphan Drug Exclusivity(ODE-418) Apr 30, 2028
Orphan Drug Exclusivity(ODE-16) Oct 14, 2018
New Chemical Entity Exclusivity(NCE) Oct 14, 2016
Orphan Drug Exclusivity(ODE) Oct 14, 2018

Drugs and Companies using DEFERIPRONE ingredient

NCE-1 date: 15 October, 2015

Market Authorisation Date: 20 April, 2018

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage

FERRIPROX family patents

Family Patents

62. Finacea patents expiration

FINACEA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211259 LEO PHARMA AS Antibiotic kit and composition and uses thereof
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 29, 2018

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage

FINACEA family patents

Family Patents

63. Firmagon patents expiration

FIRMAGON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US9579359 FERRING Method of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 24, 2013

Drugs and Companies using DEGARELIX ACETATE ingredient

NCE-1 date: 24 December, 2012

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage

FIRMAGON family patents

Family Patents

64. Fyarro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786 AADI Nanoparticle comprising rapamycin and albumin as anticancer agent
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 22, 2024
Orphan Drug Exclusivity(ODE-386) Nov 22, 2028

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma)

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FYARRO family patents

Family Patents

65. Galafold patents expiration

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592362 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(4 years from now)

US9095584 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(4 years from now)

USRE48608 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(4 years from now)

US10813921 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

66. Gelnique patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259388 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)

US10449173 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 27, 2012

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence wi...

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage

GELNIQUE family patents

Family Patents

67. Gemtesa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

GEMTESA family patents

Family Patents

68. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9701538 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2029

(4 years from now)

US9604028 VERO BIOTECH INC Systems and devices for generating nitric oxide
Aug, 2029

(5 years from now)

US8944049 VERO BIOTECH INC Systems and devices for generating nitric oxide
Aug, 2029

(5 years from now)

US10926054 VERO BIOTECH INC Systems and devices for generating nitric oxide
Aug, 2029

(5 years from now)

US11511252 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Sep, 2029

(5 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

69. Genvoya patents expiration

GENVOYA's oppositions filed in EPO
GENVOYA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Dosing Schedule(D-173) Dec 10, 2021
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

70. Giapreza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500247 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US9867863 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US10335451 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US10548943 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension; Treating refractory hy...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

71. Gilotrif patents expiration

GILOTRIF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-230) Jan 12, 2025
M(M-276) Apr 07, 2025
Pediatric Exclusivity(PED) Oct 07, 2025
Orphan Drug Exclusivity(ODE) Apr 15, 2023
New Chemical Entity Exclusivity(NCE) Jul 12, 2018
New Indication(I-730) Apr 15, 2019
Orphan Drug Exclusivity(ODE-115) Apr 15, 2023
New Indication(I-763) Jan 12, 2021
Orphan Drug Exclusivity(ODE-50) Jul 12, 2020

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

72. Gimoti patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020361 EVOKE PHARMA INC Nasal formulations of metoclopramide
Dec, 2029

(5 years from now)

US11813231 EVOKE PHARMA INC Nasal formulations of metoclopramide
Dec, 2029

(5 years from now)

US11628150 EVOKE PHARMA INC Nasal formulations of metoclopramide
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 19, 2023

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of GIMOTI before it's drug patent expiration?
More Information on Dosage

GIMOTI family patents

Family Patents

73. Givlaari patents expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

74. Glyxambi patents expiration

GLYXAMBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-739) Dec 02, 2019
New Combination(NC) Jan 30, 2018
M(M-258) Jul 03, 2022
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

75. Harvoni patents expiration

HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(4 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(4 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(5 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(5 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
ODE*(ODE*) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE) Apr 07, 2024
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Patient Population(NPP) Apr 07, 2020
New Indication(I-718) Nov 12, 2018
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-177) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

HARVONI family patents

Family Patents

76. Horizant patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8795725 AZURITY GABA analog prodrug sustained release oral dosage forms
Jun, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jun 06, 2019
Orphan Drug Exclusivity(ODE-25) Jun 06, 2019
New Chemical Entity Exclusivity(NCE) Apr 06, 2016
New Indication(I-652) Jun 06, 2015

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: Management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage

HORIZANT family patents

Family Patents

77. Ibsrela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 13 September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage

IBSRELA family patents

Family Patents

78. Inbrija patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43711 ACORDA Pulmonary delivery for levodopa
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 21, 2021

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER;INHALATION

More Information on Dosage

INBRIJA family patents

Family Patents

79. Incruse Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556 GLAXO GRP ENGLAND Medicament dispenser
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-172) Feb 24, 2019
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 30 April, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

INCRUSE ELLIPTA family patents

Family Patents

80. Inomax patents expiration

INOMAX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8282966 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Jun, 2029

(5 years from now)

US8431163 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas
Jun, 2029

(5 years from now)

US8846112 MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Jun, 2029

(5 years from now)

US8293284 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Jun, 2029

(5 years from now)

US8795741 MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment
Jun, 2029

(5 years from now)

US8795741

(Pediatric)

MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment
Dec, 2029

(5 years from now)

US8431163

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas
Dec, 2029

(5 years from now)

US8293284

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Dec, 2029

(5 years from now)

US8282966

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Dec, 2029

(5 years from now)

US8846112

(Pediatric)

MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-167) Oct 09, 2018
M(M-132) Dec 21, 2013
Pediatric Exclusivity(PED) Jun 21, 2014

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage

INOMAX family patents

Family Patents

81. Intermezzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8242131 PURDUE PHARMA Methods of treating middle-of-the-night insomnia
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 23, 2014

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 23 November, 2011

Treatment: Method of treating middle-of-the-night insomnia

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of INTERMEZZO before it's drug patent expiration?
More Information on Dosage

INTERMEZZO family patents

Family Patents

82. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
New Combination(NC) Aug 08, 2017
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

83. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.